← Back to Clinical Trials
Recruiting NCT04739319

NCT04739319 Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04739319
Status Recruiting
Phase
Sponsor Center for Eye Research Australia
Condition Age Related Macular Degeneration
Study Type OBSERVATIONAL
Enrollment 2,500 participants
Start Date 2021-02-02
Primary Completion 2040-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
N/A Observational study

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,500 participants in total. It began in 2021-02-02 with a primary completion date of 2040-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD. This proposed project is a prospective, observational study that seeks to to understand the underlying aetiology of AMD, factors associated with differences between age-related macular degeneration (AMD) phenotypes or severities, or between AMD and healthy individuals. It also seeks to understand the natural history of AMD progression and the factors associated with the rate of progression. In this project, the disease phenotype, genotype and severity and rate of progression will be determined based on non-invasive clinical imaging or functional assessment of the retina, from obtaining biological samples from the participants, or from patient-reported outcomes.

Eligibility Criteria

Inclusion Criteria: 1. 18 years of age or older; and 2. either AMD (defined as having at least a medium druse \>63 um), or having eyes with normal ageing changes (including small drusen ≤63 um) or no abnormalities as control participants Exclusion Criteria: 1. ocular or systemic conditions other than AMD that could compromise retinal assessment or assessment of AMD and its progression; or 2. any participant with any mental or physical impairment that prevents them from signing an informed consent form or participating in this study.

Frequently Asked Questions

Who can join the NCT04739319 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Age Related Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04739319 currently recruiting?

Yes, NCT04739319 is actively recruiting participants. Visit ClinicalTrials.gov or contact Center for Eye Research Australia to inquire about joining.

Where is the NCT04739319 trial being conducted?

This trial is being conducted at East Melbourne, Australia.

Who is sponsoring the NCT04739319 clinical trial?

NCT04739319 is sponsored by Center for Eye Research Australia. The trial plans to enroll 2,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology